About NexMR
NexMR is a company based in Switzerland founded in 2021 was acquired by Magritek in July 2026. NexMR offers products and services including Light-sources for high-field NMR, Ultrafast NMR Fragment library, Ultrafast NMR reagents kit, Automated screening analysis, and Automated affinity determination analysis. NexMR operates in a competitive market with competitors including Insitro, Certara, HotSpot Therapeutics, CytoReason and GRO Biosciences, among others.
- Headquarter Switzerland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NexMR
NexMR offers a comprehensive portfolio of products and services, including Light-sources for high-field NMR, Ultrafast NMR Fragment library, Ultrafast NMR reagents kit, Automated screening analysis, and Automated affinity determination analysis.
Enables 100-fold faster NMR measurements for drug discovery
Reduces sample preparation time for NMR experiments
Optimizes performance and reduces sample concentration
Provides ultrafast data analysis for screening applications
Facilitates automated determination of molecular affinities
Funding Insights of NexMR
Investors in NexMR
NexMR has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Magritek and Venture Kick.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
University backed startup accelerator
|
Locked | Locked | Locked | |
|
Provider of NMR and MRI solutions for industries and research laboratories
|
Locked | Locked | Locked |
Investor details for NexMR
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NexMR
Investment portfolio details for NexMR
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NexMR
Detailed financials for NexMR
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nexmr Comparisons
Peer comparison for NexMR
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NexMR
NexMR operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, Certara, HotSpot Therapeutics, CytoReason and GRO Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Provider of a platform for in silico drug discovery and consulting services
|
|
| Locked | Locked | Locked |
Developer of a platform for protein function analysis
|
|
| Locked | Locked | Locked |
Immune system-based drugs are discovered via biological data analytics.
|
|
| Locked | Locked | Locked |
Synthetic biology tools are developed via genetic code recoding techniques.
|
|
| Locked | Locked | Locked |
Anti-cancer small molecules are developed to target drug resistance pathways.
|
Detailed competitors of NexMR
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nexmr
Complete news archive for NexMR
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NexMR
NexMR was founded in 2021 and raised its 1st funding round 1 year after it was founded.
NexMR is headquartered in Switzerland.
NexMR was founded in 2021 in Switzerland as a provider of software solutions tailored to NMR-based drug discovery pipelines. Operations center on developing tools that support pharmaceutical research and development processes. Services include software for analyzing nuclear magnetic resonance data to streamline drug candidate identification and validation. The company maintains its headquarters in Switzerland, serving the biotech sector through its online platform at nexmr.com.
NexMR's top competitors include Insitro, HotSpot Therapeutics and Certara.
NexMR offers Light-sources for high-field NMR, Ultrafast NMR Fragment library, Ultrafast NMR reagents kit, Automated screening analysis, and Automated affinity determination analysis.
NexMR has 2 investors. Key investors include Magritek, and Venture Kick.